China
By Katy O'Donnell | September 17th, 2013

A Chinese newspaper reported today that the eye care division had paid doctors in more than 200 hospitals for phony clinical trials.

By The Financial Times | September 16th, 2013

Dumex, the baby food brand owned by France’s Danone, said on Monday it was investigating allegations on Chinese state television that the company bribed doctors and nurses to recommend its infant formula to the parents of newborns at some hospitals.

By Katy O'Donnell | September 13th, 2013

China has launched a high-profile campaign against purported corruption among foreign pharmaceutical companies this summer. UPDATED

By Douglas Gillison | September 9th, 2013

After revealing a review of sex bribery allegations in China earlier this year, Agilent now says it is investigating the use of third-party agents in that country.

By | September 6th, 2013

Expanding the investigation to include the China allegations is a routine step.

By Wall Street Journal | September 6th, 2013

U.K. laws could prevent it from pursuing a case against one of its own companies if Chinese and U.S. authorities have gotten there first.

By | August 22nd, 2013

U.S. drugmaker Eli Lilly and Co said it was “deeply concerned” about allegations published in a Chinese newspaper that it spent more than 30 million yuan ($4.90 million) to bribe doctors in China to prescribe the firm’s medicines instead of rival products.

By Douglas Gillison | August 16th, 2013

The U.S. has taken the lead on investigating the mining concern, with Australian authorities embarrassed into taking belated action.

By Katy O'Donnell | August 14th, 2013

Chinese authorities have recently brought intense pressure to bear on foreign drug makers over alleged bribery.

By Douglas Gillison | August 9th, 2013

Company directors won plaudits for the acquisition of a Chinese drug maker in 2011 but the outcome has been less rosy than it may originally have seemed.

By Katy O'Donnell | August 2nd, 2013

At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca.

By Douglas Gillison | August 1st, 2013

A low-ball initial offer is rejected and Avon says it expects to pay more for alleged bribes in China and other countries. (Subscription required)

By Main Justice staff | July 29th, 2013

Just Anti-Corruption reported the disclosure as it occurred last year. Other media suggested the disclosure was made this week.

By Katy O'Donnell | July 26th, 2013

The judge refused to approve the deal for two years without the company agreeing to file reports to both him and the SEC on any potential violation.

By Katy O'Donnell | July 17th, 2013

If GSK isn’t the only pharmaceutical company under investigation by Chinese authorities, a look to the list of drug makers whose conduct in China has also been probed by the United States may offer clues to the others.

Barnes & Thornburg LLP
ANALYSIS: FCPA/Brazil: The Perfect Storm for Anti-Corruption Enforcement more
Morgan, Lewis & Bockius LLP
ANALYSIS: SEC Recommends “Localized” FCPA Controls For Foreign Subsidiaries more
Clifford Chance
ANALYSIS: World Bank Debarment: Another Consequence of Bribery Asian Companies Need to Know more
Paul Hastings LLP
ANALYSIS: Not Finished With You Yet—The U.S. Government Extends its DPA With Biomet, Again Underscoring the FCPA... more
McGuireWoods LLP
ANALYSIS: The FCPA Implications of China’s Plan to Consolidate State-Owned Enterprises more
Ropes & Gray LLP
ANALYSIS: Courts Continue to Dismiss Shareholder Suits Based on FCPA Violations more

President Barack Obama speaks at outgoing Attorney General Eric Holder's portrait unveiling ceremony.



Attorney General Eric Holder called for a lower bar to federal civil rights prosecutions in an exit interview with Politico's Mike Allen.